myAirvo 2

Humidified high flow therapy system

Deliver humidified high flows from 2-60 L/min to chronic respiratory patients at home or in long-term care facilities.

Product enquiry

Video guides and instructions for use

myAirvo 2 system components

Learn how myAirvo™ 2 can help patients manage chronic respiratory conditions

Humidified high flow therapy has been shown to ease symptoms such as frequent coughs and breathlessness as well as reduce escalation of care in patients with conditions such as COPD.^1-4 The myAirvo 2 is an innovative humidified high flow system that delivers the therapy through an Optiflow™ nasal cannula and a trio of advanced technologies.

Discover the myAirvo 2 technology

Advanced humidity algorithm

The myAirvo 2 algorithm’s intelligent controls deliver Optimal Humidity to patients at 37, 34 or 31 °C.

myAirvo 2 air pathway

A uniquely designed air pathway thoroughly conditions the mix of air and oxygen to accurately deliver the patient’s set flow rate.

AirSpiral™ Tube

The two-spiral design produces up to 93% less condensate*, maximizing humidity levels of the breathing gas.

*When compared with Airvo tube 900PT501 in internal F&P testing

Choose between two myAirvo 2 setups

Set up with the Reusable Chamber

Engineered to last up to two years and dishwasher safe.

A. myAirvo 2 device
B. Reusable Chamber
C. Compact Stand
D. AirSpiral Tube
E. Optiflow interfaces for adult and peadiatric applications, including nasal cannula, tracheostomy and mask adapter options

Set up with the Auto-fill Chamber

Designed for use with the Water Bag for longer therapy sessions.

A. myAirvo 2 device
B. Auto-fill Chamber
C. Water Bag
D. Compact Stand
E. AirSpiral Tube
F. Optiflow interfaces for adult and peadiatric applications, including nasal cannula, tracheostomy and mask adapter options

View more myAirvo support resources

Enquire about myAirvo

If you have an enquiry about our products, please provide the following information so a Fisher & Paykel Healthcare representative can contact you. For further details on how this information will be used, see below or go to our privacy statement.

Full name*

Email Address*

Country/Region*

Postcode*

Organization Name:

Role:

I consent to Fisher & Paykel Healthcare keeping me informed about new F&P products, clinical updates, events and promotions on the following topics: Adult Respiratory Care
Pediatric Respiratory Care

Message:

Storgaard LH, et al. Long-term effects of oxygen-enriched high-flow nasal cannula treatment in COPD patients with chronic hypoxemic respiratory failure. Int J Chron Obstruct Pulmon Dis 2018;13:1195-1205. View abstract
Storgaard LH, et al. COPD Patients’ Experience of Long-Term Domestic Oxygen-Enriched Nasal High Flow Treatment: A Qualitative Study. COPD. 2020;17(2). View abstract
Rea H, et al. The clinical utility of long-term humidification therapy in chronic airway disease. Respir Med 2010;104:525-533. View abstract
Nagata K, et al. Home High-Flow Nasal Cannula Oxygen Therapy for Stable Hypercapnic COPD Patients: A Randomized Trial. American Journal of Respiratory and Critical Care Medicine. 2022, 206 (11). View abstract

View references

F&P, myAirvo, Airvo, AirSpiral and Optiflow are trademarks of Fisher & Paykel Healthcare Limited. For patent information, see www.fphcare.com/ip